Pettääkö muisti yhä useammin ?

Introduction

The Department of Neurology is a research center with experience in basic and clinical neurosciences. Researchers and staff are totaling 60. The research groups in Canthia Building focus on basic mechanisms, prevention, drug and clinical research of degenerative brain diseases, particularly Alzheimer's disease, stroke and epilepsy. Most population-based surveys and drug trials are run at the Brain Research Unit in Clinical Research Centre. There are also facilities for genetics and biomarker analysis for  searching new risk genes using single nucleotide polymorphism analysis and functional studies.

High level of knowledge creates results

Since 1990, our PhD students have produced 93 doctoral dissertations. Annually, we produce 50-60 publications in international scientific journals. We are part of the drug development network at the Kuopio University campus. 

Developing neuroimaging techniques to understand pathogenesis

We have developed techniques to measure earliest changes in Alzheimer brains and provided evidence that epilepsy can be a progressive process leading to neuronal death.  We are applying diffusion magnetic resonance imaging for early identification of the extent of the ischemia.  With help of these advanced imaging techniques we can assess efficacy of new drugs in the future.

Slowing down progression and delaying onset

---

We are partners:

Biocenter Kuopio: "...aims at building up a multidisciplinary research network between different actors in the fields of molecular medicine and related drug research and biotechnology"

LipiDiDiet: "Therapeutic and preventive impact of nutritional lipids on neuronal and cognitive performance in aging, Alzheimer's disease and vascular dementia"

Nordic Centre of Excellence: "... to try to understand what Alzheimer's, Parkinson's and Huntington's diseases have in common and if they can be prevented with new treatments"

PredictAD: "... research project aiming at developing a standardised and objective solution that would enable an earlier diagnosis of Alzheimer’s disease, improved monitoring of treatment efficacy and enhanced cost-effectiveness of diagnostic protocols"